Research progress of new intravesical therapies for non-muscle invasive bladder cancer

VernacularTitle:非肌层浸润性膀胱癌新型腔内治疗研究进展
Author: Zeji MENG ¹ ; Kaijie WU
Author Information

1. 西安交通大学第一附属医院泌尿外科,陕西西安 710061
Keywords: bladder cancer; non-muscle invasive bladder cancer; BCG failure; new intravesical therapies
From: Journal of Modern Urology 2024;29(6):560-565
CountryChina
Language:Chinese
Abstract: Bladder cancer is one of the most common urinary tumors.About 70％of the cases are non-muscle invasive bladder cancer(NMIBC)at the time of initial diagnosis while the recurrence rate is as high as 31％to 78％within 5 years.Furthermore,17％to 45％of the patients will develop muscle-invasive bladder cancer(MIBC)later.At present,the traditional chemical drugs and BCG intravesical therapy can no longer meet the clinical needs,and some systematic treatments have been applied to the patients with BCG failure.In recent years,a variety of new intravesical therapies,including immune gene therapy,photodynamic treatment and new combination of drugs and equipment,have been put into clinical applications.This article will review the novel research progress and provide a new direction for the treatment of NMIBC.